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OBJECTIVES: Biologic treatments for rheumatoid arthritis (RA) vary widely in both
the time required to administer treatment and treatment frequency. The primary
aim of this study is to quantify the tradeoffs RA patients are willing to make be-
tween treatment time and frequency. METHODS: Patients with a self-reported
physician diagnosis of moderate-to-severe RA completed aWeb-enabled conjoint-
analysis survey. Severity of self-reported symptoms was determined by the Rou-
tine Assessment of Patient Index Data 3 (RAPID3) score. Patients were presented
with a series of treatment-choice questions. Each hypothetical treatment included
six attributes: response rate, mode of administration, treatment time, treatment
frequency, and the risks of immediate, mild and serious treatment reactions. Pref-
erence weights were estimated using mixed-logit and were used to calculate the
relative importance of treatment attributes and the marginal rate of substitution
between treatment time and frequency (MRS). RESULTS: A total of 901 patients
completed the survey. The risk of serious treatment reaction was the most impor-
tant attribute followed by the frequency of treatments and treatment response
rate, which were equally important. The risk of a mild treatment reaction was the
least important attribute. The MRS implies that if the duration of a 4-hour infusion
administered 4 times per year were reduced to 2 hours: 1) the frequency would
have to be 10.4 times per year to keep utility constant; 2) the frequency of a 4 hour
infusion administered 4 times per year would have to be reduced to 1.6 times per
year to generate an equivalent change in utility; and 3) there would be a 50%
increase in predicted probability of choosing the treatment if all other attributes of
this and other RA treatments were unchanged. CONCLUSIONS: Convenience of RA
treatment is important to RA patients. Treatment duration and frequency likely
play an important role in patients’ choice of RA treatment.
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OBJECTIVES: The availability of biologic therapies has increased the complexity of
treatment decisions in juvenile idiopathic arthritis (JIA). There are important dif-
ferences in the effectiveness, safety, convenience and cost of these treatments
compared to other therapeutic agents. High costs and restricted public funding also
limit access to biologics in JIA. The objective of this research was to determine
parents’ willingness-to-pay (WTP) for attributes related to drug treatments in JIA
and for profiles reflecting methotrexate (MTX) and etanercept (ETN). METHODS:
WTP was determined using parameter estimates from a discrete choice experi-
ment. Marginal WTP was estimated as the ratio of an attribute divided by the
negative of the cost attribute. Average WTP for MTX and ETN profiles were esti-
mated using expected compensating variation. Bootstrapping was used to gener-
ate 95% confidence intervals for all WTP estimates. RESULTS: Parents had the
highest WTP for improved participation in daily activities and pain relief followed
by the elimination of treatment side-effects. Parents were willing to pay $2,080
(95% CI $698, $4,065) more for ETN than MTX. When MTX was associated with no
side-effects, or was assumed to be equally effective as ETN, parents were willing to
pay $985 (95% CI $402, $2,882) more for ETN or no more (95% CI -$596, $488)
respectively. CONCLUSIONS: Parents’ WTP represents a monetary equivalence of
utility for drug treatments in JIA and their desire for treatments that reduced pain,
improved daily functioning and eliminate side-effects. These findings align with
recent guidelines which recommend more aggressive therapies for children with
JIA. Unfortunately, high costs and limited access to biologic drugs in Canada pre-
vents many children from receiving the most effective treatment. Findings from
this study will be used to inform policy decisions surrounding the future of pre-
scription drug programs for JIA and other chronic pediatric conditions.
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OBJECTIVES: To evaluate IV golimumab(GLM) on HRQol and work productivity in
RA. METHODS: Patients with active RA despite MTX(6TJC&SJC,CRP1.0mg/
dL,and RF and/or anti-CCP) were randomized to placeboMTX(placebo group) or
GLM2mg/kgMTX(GLM group) at wk0,2,and q8wk,thereafter.Patients in placebo
group with10% improvement in TJC&SJC from baseline at wk16 entered early
escape and received IV GLM2mg/kg infusion at wks16 and 20 and
q8wks,thereafter.HRQol was assessed using SF-36 and EQ5D(five-item descrip-
tive system of health states and a visual analog scale[EQ VAS,0-100]).Scores for
the five health states were converted into a utility score(EQ5D index,0-
1,0dead,1full health)using the US D1 model.Impact of disease on daily work
productivity was assessed using VAS 0-10(0no affect,10affected very much-
).Clinically meaningful improvements were defined as change of5 points in
SF-36 PCS and MCS or a change in magnitude of half of standard deviation in
EQVAS and EQ5D index.Correlation of remission measured by DAS28(using
CRp2.6) with change in PCS and MCS,and productivity scores were analyzed-
.Comparisons performed using ANOVA on van der Waerden normal scores for
continuous outcomes or Chi-square test for binary outcomes. RESULTS:At base-
line,mean(SD)SF-36 PCS(30.86.95)andMCS(37.611.28)were below the US
norm(50).Impact of disease on daily work productivity was 6.4(2.32).Compared to
placebo,significantly greater changes were observed in the GLM-treatment group
inSF-36 PCS(5.92vs3.19),SF-36MCS(4.91vs1.46),EQVAS scores(11.43vs2.53) and EQ5D
index(0.13 vs0.09) at wk12,which were sustained through wk16 and 24(p-
values0.01).Compared to placebo,a greater proportion of patients in the GLM
group achieved clinically meaningful improvement in SF-36PCS,SF36MCS,EQVAS
and EQ5Dindex.Significantly greater improvements in 8 SF-36 sub-scores for the
GLM group vs placebo,were observed(p 0.001).At wk24,mean change(improve-
ment) from baseline in impact of disease on daily work productivity was signifi-
cantly better in GLM group vs placebo(-2.78vs-1.03,p0.001).Change in SF-36 and
work productivity were correlated with change in DAS28,and those who achieved
DAS28 remission had greater improvement in SF-36 PCS,MCS and productivity VAS
scores than those who didn’t achieve remission. CONCLUSIONS: IV GLM signifi-
cantly improved HRQol and work productivity in RA.
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OBJECTIVES: To evaluate the association of fatigue with physical function and
disease activity in RA patients and the impact of treatment with IVgolimumab-
(GLM)on fatigue.METHODS:GO-FURTHERwas a PhaseIII,multicenter, randomized,
placebo-controlled study. Adult patientswith active RAdespiteMTXwere random-
ized to placeboMTX(placebo group) or IV GLM2mg/kgMTX (GLM group) at wk0,2,
and q8wks thereafter. Patients in placebo group with 10% improvement in TJC/
SJC from baseline at wk16 entered early escape and received 2mg/kg GLM infusion
at wks16 and 20. Impact on physical function was assessed using the disability
index of the HAQ. Fatigue was measured using FACIT-F questionnaire, and clini-
cally meaningful improvement in FACIT-Fatigue was defined as 4 point increase
in scores. Correlation of FACIT-Fatigue with HAQ and disease activity and remis-
sion (DAS28 using CRp2.6) were analyzed using Pearson correlation, or multiple
linear and logistic regression models to adjust for other confounding variables
(age,CRP,TJC, SJC). Comparisons were performed using ANOVA on van der
Waerden normal scores for continuous outcomes or Chi-square test for binary
outcomes. RESULTS: At baseline,mean(SD) FACIT-Fatigue score was 25.5(10.54),
indicating significant fatigue.Significant correlations of FACIT-Fatigue with
HAQ(r-0.62,p0.01) and DAS28 score(r-0.42,p0.01) were observed at baseli-
ne.Inmultiple regressionmodels,baseline FACIT-Fatigue score or change in FACIT-
Fatigue atwk24were correlatedwith change inHAQandDAS28 score.Patientswith
higher FACIT-Fatigue scores at baseline were more likely to achieve DAS28 remis-
sion at wk24(p0.024).Compared to placebo,GLM-treated patients had significantly
greater improvement in FACIT-Fatigue at wk12(5.410.3 vs. 2.19.0),which was
sustained through wk16(7.510.5 vs. 2.29.7) and 24(8.010.8 vs. 2.510.2) (all
p-values0.001). Compared with placebo,a greater proportion of patients in the
GLM group achieved clinically meaningful improvement in FACIT-Fatigue score at
wk12(57.5% vs. 42.8%) and wk24(65.8% vs.40.3)(p-values0.001). CONCLUSIONS:
Fatigue was a significant independent predictor of physical function and disease
activity in RA patients.IV GLM significantly improved clinical symptoms of fatigue
in RA patients with inadequate response to MTX.
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OBJECTIVES: Quantify the relative difference in improvement in patient-reported
outcomes between rheumatoid arthritis (RA) patients achieving different T2T-re-
lated goals versus those who do not. METHODS: This is a post hoc analysis of the
RESTART trial, an active switch study, where patients were treated with IFX for 22
weeks and clinicians allowed to dose escalate at fixed intervals to achieve a EULAR
response. In this analysis, multiple analytical sub-groups were defined using real-
world CDAI thresholds. Given high baseline Clinical Disease Activity Index (CDAI)
scores, sub-group definitions included goals of low or moderate disease activity,
with or without significant improvement in CDAI. Sub-group response thresholds
at Week 26 included real-world specific cut points of: CDAI19.6 (Sub-group A);
CDAI19.6 AND CDAI reduction of at least 10 points (Sub-group B); CDAI7.6 (Sub-
group C). Within each sub-group, responder versus non-responder cohorts were
compared on HAQ scores and all domains of the SF-36. Descriptive statistics and a
non-parametric Wilcoxon test were used to compare cohorts. RESULTS: Respond-
ers in Sub-groups A to C typically experienced 2 to 3 times the level of absolute
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improvement from baseline to week 26, in 7 of 8 SF-36 domains, versus non-re-
sponders, and 2 to 8 times greater improvement in HAQ. Patients attaining low
disease activity (Sub-group C) experienced the greatest differences. For Sub-group
B, where cohorts had the most comparable baseline scores, results were statisti-
cally significant for HAQ (p0.0012) and 6 of 8 SF-36 domains (p0.01 except role-
emotional and mental health domains). CONCLUSIONS: Patients able to attain
T2T-related response achieved significantly greater absolute improvement in
health status versus non-responders, in HAQ and 6 of 8 SF-36 domains. There may
be additional value in adding change scores to threshold values in current T2T
objectives for severe patients and consideration of patient functionality may be
warranted.
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OBJECTIVES: To describe the shared decision-making process between patients
and physicians when initiating biologic therapy for the treatment of rheumatoid
arthritis (RA) from the patient perspective. METHODS: Patients self-reporting a
diagnosis of RA completed a self-administered, internet-based questionnaire in
the Fall of 2011. A subset of patients currently using a biologic therapy to treat their
RA provided details about the decision-making process for initiating their current
therapy. RESULTS: A total of 2138 respondents (76% female, mean age 56.4) com-
pleted the questionnaire. Of these, 20% (n434) were currently being treated with
biologic therapy. Discussions about biologic therapy weremost often initiated by a
rheumatologist (91%); only a small proportion of patients reported that a primary
care physician (4%), the patient themselves (3%), or another (2%) initiated the dis-
cussion. During the discussions, physicians most often focused on administration
(77%), dosing schedule (77%), side effects (71%), safety risks (64%), importance of
long-term use (57%), and importance of concomitant methotrexate use (53%). Pa-
tients rated the following as very or extremely influential (4 or 5 on a 5-point Likert
scale) on the final decision to initiate biologic therapy: advice or recommendation
by physician (76%), co-pay assistance to cover out-of-pocket costs (31%), advice or
recommendation from other healthcare professional (28%), patient literature ma-
terials from physician office (27%), and information from general websites (22%).
Most patients (71%) reported making the decision to start biologic therapy at the
time of the initial discussion with their physician; mean time for all patients to
make a decision to start biologic therapy was 12.2 days from the time of initial
discussion. CONCLUSIONS: Rheumatologists are best positioned to ensure that
patients have the necessary information to actively engage in the shared decision-
making process for initiating biologic therapy. Future research should focus on
potential outcomes benefits of shared decision-making.
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OBJECTIVES: Remission by Boolean-based definition(all scores on the TJC and SJC-
,CRP(mg/dl), and PGA1) and by SDAI(3.3) were proposed by ACR/EULAR.Using
patient reported outcomes as anchors, this analysis validated these remission cri-
teria against traditional DAS28(using CRp2.6)remission. METHODS: Efficacy of
golimumab(GLM) was assessed in MTX-naïve RA patients(GO-BEFORE, N637),
RA patients with inadequate response to MTX (GO-FORWARD,N444) and RA
patients previously treated with biologic anti-TNF agent(s) with baseline MTX
use(GO-AFTER,N305).Pooled data from patients who received placebo
(PBO)MTX, or GLM(50or100mg)MTX,q4wks were used for this analysis.Pa-
tient reported outcomes were measured using:HAQ, SF-36 PCS and MCS, FACIT-
Fatigue, and VAS 0-10 of impact of RA on daily work productivity.Descriptive
statistics were provided for patient reported outcomes among patients in re-
mission as defined remission definitions. RESULTS: Greater proportions of pa-
tients treated with GLMMTX vs patients treated with PBOMTX achieved remis-
sion by each remission definition.In the pooled analysis,the remission rate at wk24
was the highest(20.2%)by DAS28 vs remission by SDAI(10.6%, p0.001) and remis-
sion by Boolean-based definition(8.6%p0.001).Patients with remission by DAS28
achieved normal physical function(HAQ0.5),normal SF-36PCS and MCS(50) by
67.8%,38.4%,62.2%,respectively;these parameters were numerically lower vs. pa-
tientswith remission by SDAI(81.3%,62.8%,72.1%,respectively) or by Boolean-based
definition(82.0%,63.5%,74.3%, respectively). Patients in remission by DAS28 had
higher HAQ scores(0.430.49)vs patients in remission by SDAI(0.260.41) or Bool-
ean-based criteria(0.280.44).Similar results were observed in measures of FACIT-
Fatigue and productivity VAS scores.Among MTX-naive patients in GO-BEFORE
who achieved remission by DAS28,71.3% achieved normal physical function vs
86.9% of those in remission by SDAI and 86.5% of patients in remission by Boolean-
based definition.Among anti-TNF experienced patients in GO-AFTER,62.1% of
those in remission by DAS28 achieved normal physical function vs. 65.0% of those
in remission by SDAI, and 66.7% of patients in remission by Boolean-based
definition.CONCLUSIONS:While disease remission has been adapted as a target in
the management of RA, more stringent remission criteria proposed by ACR/EULAR
can provide optimal patient-reported outcomes.
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OBJECTIVES: To examine the relationship of health care costs with baseline demo-
graphic and clinical characteristics for rheumatoid arthritis (RA) patients.
METHODS: Adult RA patients (ICD-9: 714.XX) treated with anti-tumor necrosis
factors (anti-TNFs) were identified from a large US commercial claims database
(June 2004-June 2009). Patientswho switched to another anti-TNF or escalated their
dosage were identified between the initial anti-TNF date and June 2008. Total and
RA-related health care costs were calculated during the 12-month period after
switch or dose escalation. Scatter plots and box plots were drawn to examine the
relationship between age, gender, comorbidity indexes, baseline costs and total
all-cause and RA-related health care costs. RESULTS: A total of 2587 RA patients
with a mean age of 55.9 were included in the final sample. 23.5% of these patients
were insured by Medicare and 76.5% by commercial health plans. Scatter plots
illustrate a slightly positive relationship between age and total health care costs in
the commercial population. Moreover, a stronger positive trend exists between the
Charleston Comorbidity Index (CCI) and total health care costs but not with RA-
related health care costs in the commercial population. Chronic Disease Score
(CDS) shows the same trend as CCI. A positive relationship can also be seen be-
tween baseline health care costs and follow up all-cause or RA-related costs. The
majority of observationswere clustered at the lower end of the domain.We further
examined the relationships in the patient populations treated with and without
methotrexate, and the results were similar. CONCLUSIONS: There were strong
positive relationships between baseline and follow-up health care costs among RA
patients who initiated anti-TNFs and subsequently switched to another drug or
escalated their dosage. The positive relationships between CCI and CDSweremore
prominent in the commercially-insured patient population.
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OBJECTIVES: To develop and test an ePRO system for routine collection of surgical
outcomes in a busy orthopaedic clinic. METHODS: We developed an ePRO (iPad)
version of the widely adopted Oxford Knee (OKS) and Shoulder (OSS) scores. A
multi-stage process was undertaken to ensure ePRO versus paper version equiva-
lence involving the PRO instrument developer, PROmanager, PRO translation spe-
cialists as well as surgeons and Electronic Management Record (EMR) hospital
specialists. This included, a review of the draft ePRO version; pilot-testing (cogni-
tive debriefing and usability testing) on five patients attending an outpatients clin-
ic; with pilot-tested results reviewed to ensure no issues arose during migration to
ePRO. RESULTS: The ePRO version of both questionnaires were shown, from pilot-
testing, to be easy to use. Compared with OKS and OSS paper versions, ePRO re-
sponses were all legible (an issue for some Rheumatoid patients) and complete.
ePRO completion also takes care of data entry, resulting in a dataset free of errors
that might otherwise arise. This suggested the potential for higher return rates
with reducedhandling costs. Following reviewof pilot-testing, no significant issues
were identified, so the final ePRO versionswere adopted. Secure synchronisation of
the completed ePRO results with the local EMR system proved straight-forward,
required little data cleaning and provided almost immediate feedback of outcomes
to clinicians. CONCLUSIONS: Initial results demonstrated the OKS and OSS have
been successfully migrated to the ePRO (iPad) version, with results from pilot-
testing demonstrating that the validity of the original PRO instrument is retained.
ePRO completion enters scores instantaneously on the local EMR system and as a
result routine collection of a high volume of PROs could be achieved efficiently.
This development facilitates the collection of PRO measure data within the clinic
setting, highlighting their potential to enhance patient-centred care across the
patients care pathway.
PMS55
QUALITY OF LIFE AMONG PATIENTS WITH SELF-REPORTED RHEUMATOID
ARTHRITIS: A NATIONALLY REPRESENTATIVE SAMPLE
Rappaport H
University of Louisiana at Monroe, Monroe, LA, USA
OBJECTIVES: To compare the health-related quality of life of patients with self-
reported Rheumatoid Arthritis to statistically matched patients without Rheuma-
toid Arthritis. METHODS: The study utilized a cross-sectional population-based
design, in which respondents, representing non- institutionalized adults in the
United States of ages 18 or above, were chosen from the 2006 Medical Expenditure
Panel Survey (MEPS). Respondents were included in the self-reported Rheumatoid
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